Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy

Total tumor clearance through immunotherapy is associated with a fully coordinated innate and adaptive immune response, but knowledge on the exact contribution of each immune cell subset is limited. We show that therapy-induced intratumoral CD8⁺ T cells recruited and skewed late-stage activated M1-like macrophages, which were critical for effective tumor control in two different murine models of Cancer Immunotherapy. The activated CD8⁺ T cells summon these macrophages into the tumor and their close vicinity via CCR5 signaling. Exposure of non-polarized macrophages to activated T cell supernatant and tumor lysate recapitulates the late-stage activated and tumoricidal phenotype in vitro. The transcriptomic signature of these macrophages is also detected in a similar macrophage population present in human tumors and coincides with clinical response to immune checkpoint inhibitors. The requirement of a functional co-operation between CD8⁺ T cells and effector macrophages for effective immunotherapy gives warning to combinations with broad macrophage-targeting strategies.

CCR5 attraction; CXCL9/CXCL10; M1 macrophages; T cell-macrophage interactions; cancer immunotherapy; coordinated immunity; effector macrophages; immune checkpoint inhibition; macrophage skewing.